Opus Genetics, Inc. (IRD) Stock Forecast & Price Target
Opus Genetics, Inc. · NASDAQ
$3.36+0.28 (+9.09%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Opus Genetics, Inc, 11 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $7.00 to $16.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $11.00 sits 227% above the current $3.36. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 10 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy11100%
Hold00%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Opus Genetics, Inc.
As of Jul, 11 of 11 firms rate IRD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IRD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.20 – $-0.11 · 12 analysts · -37% YoY
Next period, 12 analysts expect Opus Genetics, Inc. to earn $-0.16 a share (range $-0.20 – $-0.11), versus $-0.25 a year earlier. Full-year consensus is $-1.00, growing to $-0.76 the year after.
REVENUE · NEXT QUARTER
$2.8M
Range $0 – $5.0M · 12 analysts · -8% YoY
Revenue is expected to reach $2.8M (range $0 – $5.0M), -7.6% year-over-year. Full-year consensus is $15.2M, rising to $14.8M next year.
Top analysts covering Opus Genetics, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRD.
#1
Mayank Mamtani
B. Riley Securities · Rank #9
Buy
$9.00+167.9% to target
Overall win rate
53%
+ Follow
#2
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$11.00+227.4% to target
Overall win rate
55%
+ Follow
#3
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$11.00+227.4% to target
Overall win rate
44%
+ Follow
#4
MC
Matthew Caufield
HC Wainwright & Co. · Rank #51
Buy
$8.00+138.1% to target
Overall win rate
56%
+ Follow
#5
James Molloy
Alliance Global Partners · Rank #385
Buy
$9.00+167.9% to target
Overall win rate
25%
+ Follow
IRD stock forecast FAQ
What is IRD's average 12-month price target?+
The 11 analysts with a live target average $11.00 for Opus Genetics, Inc. over the next 12 months, ranging from a $16.00 high to a $7.00 low.
Is IRD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 11 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IRD?+
The Street-high target is $16.00 (Guggenheim), and the Street-low is $7.00 (Piper Sandler). The average of all 11 active targets is $11.00.
How many Wall Street analysts cover IRD?+
11 analysts have an active rating on Opus Genetics, Inc., and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering IRD?+
Among analysts who currently cover IRD, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #9). Their current call is Buy with a $9.00 target.
What is Opus Genetics, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.20 – $-0.11) across 12 analysts. Full-year EPS is projected at $-1.00, rising to $-0.76 the following year.
How much revenue is Opus Genetics, Inc. expected to report next quarter?+
Consensus revenue is $2.8M (range $0 – $5.0M). Full-year revenue is projected at $15.2M, growing to $14.8M next year.
Have analysts been upgrading or downgrading IRD lately?+
As of Jul, 11 of 11 firms rate IRD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
Chardan Capital
